DrugPatentWatch Database Preview
Impact Company Profile
» See Plans and Pricing
What is the competitive landscape for IMPACT, and what generic alternatives to IMPACT drugs are available?
IMPACT has one approved drug.
There are four US patents protecting IMPACT drugs.
There are seventy-five patent family members on IMPACT drugs in thirty-four countries.
Summary for Impact
| International Patents: | 75 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Impact
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Impact | INREBIC | fedratinib hydrochloride | CAPSULE;ORAL | 212327-001 | Aug 16, 2019 | RX | Yes | Yes | 7,825,246 | Start Trial | Y | Start Trial | |||
| Impact | INREBIC | fedratinib hydrochloride | CAPSULE;ORAL | 212327-001 | Aug 16, 2019 | RX | Yes | Yes | 10,391,094 | Start Trial | Y | Start Trial | |||
| Impact | INREBIC | fedratinib hydrochloride | CAPSULE;ORAL | 212327-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| Impact | INREBIC | fedratinib hydrochloride | CAPSULE;ORAL | 212327-001 | Aug 16, 2019 | RX | Yes | Yes | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Impact Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Mexico | 2013005020 | Start Trial |
| Peru | 20140389 | Start Trial |
| Japan | 2013056930 | Start Trial |
| World Intellectual Property Organization (WIPO) | 2012061833 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
